海马益智散治疗脑卒中后不同程度认知功能障碍的临床观察

发布时间：2018-03-08 04:20

本文选题：海马益智散　切入点：脑卒中后认知功能障碍　出处：《新疆医科大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的:评价海马益智散治疗不同程度的脑卒中后认知功能障碍(Post stroke cognitive impairment,PSCI)患者的临床疗效,为海马益智散的临床应用提供依据。方法:选取2014—2015年乌鲁木齐市中医医院收治的PSCI患者180例,由患者本人或其家属签署知情同意书,志愿受试。(知情同意书详情见附表1)。通过画钟试验(CDT)作出痴呆程度(0-1分为重度,2分为中度,3分为轻度)的判定,分为轻度、中度、重度(A组、B组、C组),遵循随机对照原则,采用随机数字表法各组再分为实验组(A1组、B1组、C1组)与对照组(A2组、B2组、C2组),2组均给予常规西药治疗,治疗组在此基础上加服海马益智散。治疗3个月后观察2组蒙特利尔认知评估表(Montreal cognitive assessment,Mo CA)和日常生活能力量表(Activities of daily living,ADL)、简易精神状态检查表(Mini-Mental State Examination,MMSE)、中医症状积分值评分变化。结果:在两组间患者年龄、性别等相关因素经统计学处理,具有可比性的前提下,轻中度患者治疗后MMSE、Mo CA、ADL及中医证候积分均有所改善,与治疗前比较(P0.05)差异均有显著性意义,重度患者治疗前后差异无显著意义,治疗后各治疗组和对照组MMSE、Mo CA、ADL分值组间对比(P0.05),差异均无显著性意义,中医证候积分值组间对比(P0.05)差异有显著性意义。结论:海马益智散治疗轻中度PSCI患者的临床疗效确切,可明显改善轻中度PSCI患者的认知能力、日常生活能力及相关中医症候,在中医症候的疗效改善方面,海马益智散较尼莫地平片显效。能提高患者的生活质量,有利于轻中度PSCl患者的转归预后向积极的方向发展,值得推广应用。
[Abstract]:Objective: to evaluate the clinical efficacy of Hippocampal Yizhi Powder (YZS) in the treatment of post stroke cognitive impairment (PSCI) patients with different degree of cognitive dysfunction after stroke. Methods: 180 PSCI patients treated in Urumqi traditional Chinese Medicine Hospital from 2014-2015 were selected and informed consent was signed by the patients themselves or their families. Voluntary subjects. (see schedule 1 for details of informed consent forms. Using bell drawing test CDT) to determine the degree of dementia from 0-1 to 2 to moderate to 3 to mild), divided into mild, moderate and severe group A, B, C, followed the principle of randomized control. Each group was subdivided into experimental group (group A 1) and group B 1 (group C 1) and control group (group A 2) and group B 2 (group C 2) were treated with routine western medicine. After 3 months of treatment, the two groups were observed the activities of daily activities of daily activities and activities of daily activities, mini-mental State examination, MMSE, and TCM symptom score after 3 months of treatment, the two groups were treated with Montreal cognitive assessment and CAA) and the activity of daily activities of activities of daily living scale (ADL), the mini-mental state examination form (Mini-Mental State examination), and the symptom score of traditional Chinese medicine (TCM) were observed after 3 months of treatment. Results: the age of the patients between the two groups, On the basis of statistical analysis and comparability of sex and other related factors, MMSE Mo CAG ADL and TCM syndromes scores were improved after treatment in mild and moderate patients, and there were significant differences compared with those before treatment (P 0.05). There was no significant difference before and after treatment in severe patients. There was no significant difference in the scores of MMSE Mo CAG ADL between the treatment group and the control group before and after treatment (P 0.05). Conclusion: HYZS is effective in the treatment of mild and moderate PSCI patients, and can obviously improve the cognitive ability, daily living ability and related TCM symptoms in patients with mild and moderate PSCI. In the aspect of improving the curative effect of TCM symptoms, Yizhi Powder of hippocampus is more effective than nimodipine tablet, which can improve the quality of life of patients, and is beneficial to the prognosis of patients with mild and moderate PSCl to a positive direction, which is worth popularizing.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R749.13

【相似文献】